標(biāo)題: Titlebook: Clinical Metabolomics Applications in Genetic Diseases; Anas M. Abdel Rahman Book 2023 The Editor(s) (if applicable) and The Author(s), un [打印本頁] 作者: JAR 時間: 2025-3-21 16:38
書目名稱Clinical Metabolomics Applications in Genetic Diseases影響因子(影響力)
書目名稱Clinical Metabolomics Applications in Genetic Diseases影響因子(影響力)學(xué)科排名
書目名稱Clinical Metabolomics Applications in Genetic Diseases網(wǎng)絡(luò)公開度
書目名稱Clinical Metabolomics Applications in Genetic Diseases網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Clinical Metabolomics Applications in Genetic Diseases被引頻次
書目名稱Clinical Metabolomics Applications in Genetic Diseases被引頻次學(xué)科排名
書目名稱Clinical Metabolomics Applications in Genetic Diseases年度引用
書目名稱Clinical Metabolomics Applications in Genetic Diseases年度引用學(xué)科排名
書目名稱Clinical Metabolomics Applications in Genetic Diseases讀者反饋
書目名稱Clinical Metabolomics Applications in Genetic Diseases讀者反饋學(xué)科排名
作者: 寬度 時間: 2025-3-21 23:02 作者: FLINT 時間: 2025-3-22 01:17
Anas M. Abdel RahmanReviews recent breakthroughs in clinical metabolomics research using high-throughput approaches.Explores the principles and applications of metabolomics technologies for studying genetic diseases.Cove作者: Fabric 時間: 2025-3-22 07:51 作者: 有機(jī)體 時間: 2025-3-22 08:49
https://doi.org/10.1007/978-3-658-11366-7abolomics data in conjugation with metabolic pathways, including other omics datasets, to produce a network of endogenous metabolites (metabotype) associated with the phenotypes. Nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry are the main analytical techniques in combination wit作者: 率直 時間: 2025-3-22 14:00 作者: 率直 時間: 2025-3-22 17:21 作者: investigate 時間: 2025-3-23 01:02
Jahrbuch für Friedens- und Konfliktforschungtion of disease mechanisms. This chapter introduces readers to some of the bioinformatic tools that can be used to facilitate clinical metabolomics and provide key insights into disease processes. In particular, readers will be introduced to several important bioinformatic tools and resources in cli作者: nullify 時間: 2025-3-23 04:52 作者: 純樸 時間: 2025-3-23 09:31
Jahrbuch für Friedens- und Konfliktforschungetabolic pathways of physiologically active cells and tissues, along with an improved resolution of high-throughput screening capabilities, brought forth the clinical metabolome. Clinicians can now take a metabolic snapshot while assessing their patients and receive invaluable information on patholo作者: fetter 時間: 2025-3-23 12:40
https://doi.org/10.1007/978-3-322-86202-0 mitochondria is ATP production through oxidative phosphorylation (OXPHOS). Mitochondria are found in nearly all cell types, and their number within cells varies in a tissue?/organ-dependent manner. Tissues/organs characterized by high-energy demands contain abundant mitochondria, and these tissues/作者: Substitution 時間: 2025-3-23 17:18
https://doi.org/10.1007/978-3-322-86202-0ique metabolomic disease profiles. In the last few years, metabolomic-derived biomarkers and quantitative traits have helped identify the underlying mechanisms for many rare endocrine diseases and demonstrated a high potential for use in precision medicine. Using the metabolomic platform has also pr作者: HIKE 時間: 2025-3-23 20:32 作者: ONYM 時間: 2025-3-24 00:54
,Kernwaffen und regionale Stabilit?t,medicine to the right patient. The breathtaking boost in metabolomic technology has paved the huge potential for its application in personalized medicine. Correlating the metabolic phenotype of individuals into subgroups that respond differently is also becoming a reality through metabolomics. The p作者: 流眼淚 時間: 2025-3-24 02:32
,Rüstungsaltlasten als Verwaltungsaufgabe,ved in health and disease. Currently, many lipidomic profiling applications are moving from research laboratories to clinical application, as lipidomics has the potential to be implemented into the clinical routine, complementing traditional clinical factors to improve the diagnosis, to stratify ris作者: 離開就切除 時間: 2025-3-24 08:18 作者: Genetics 時間: 2025-3-24 13:12
The Mechanism of Action of rTMS,ment, or disease. This is challenging due to the structural diversity of the metabolites and the complexity of samples of interest, such as blood and urine, useful in population studies to study biological changes in large cohorts. The limited number of commercially available standards and incomplet作者: enhance 時間: 2025-3-24 15:03
Paul B. Fitzgerald,Z. Jeff Daskalakisosis in the lung interstitium, that is, the septum between alveoli and the blood capillaries. The clinical presentation of ILD is complex and the diagnosis is often challenging. Therefore, the need to establish disease-specific molecular fingerprints to better understand the underlying pathogenesis 作者: 黑豹 時間: 2025-3-24 19:42 作者: 后退 時間: 2025-3-25 01:33
etabolism, primary immunodeficiency, and endocrine disorders. However, integrating metabolomics with other omics datasets and clinical phenotypes requires careful study design, analytical tools, and data analys978-981-99-5164-2978-981-99-5162-8作者: 濕潤 時間: 2025-3-25 03:45
Book 2023is model has been successfully applied in various conditions, including inborn errors of metabolism, primary immunodeficiency, and endocrine disorders. However, integrating metabolomics with other omics datasets and clinical phenotypes requires careful study design, analytical tools, and data analys作者: Merited 時間: 2025-3-25 08:31 作者: countenance 時間: 2025-3-25 12:59
Clinical Metabolomics Applications in Genetic Diseases978-981-99-5162-8作者: Mechanics 時間: 2025-3-25 16:01
The Advanced Technology and Clinical Application in Metabolomics,t underlie various physiological conditions and diseases. This chapter highlights analytical methods for clinical metabolomics research and personalized medicine. Several innovative clinical metabolomics projects have reached up to patient services are discussed in this chapter.作者: 機(jī)密 時間: 2025-3-26 00:00 作者: 鍵琴 時間: 2025-3-26 03:02
Metabolomics: A Pipeline for Biomarker Discovery in Genetic Diseases,biomarker discovery in GD. It discusses the workflow followed, the methods used for sample analysis and data interpretation, and the major challenges and limitations in applying the metabolomic approach for biomarker discovery in GD. Moreover, the chapter provides an overview of the biomarkers ident作者: 收養(yǎng) 時間: 2025-3-26 08:20
Bioinformatic Tools for Clinical Metabolomics,se), data analysis and biomarker discovery tools such as MetaboAnalyst, and resources for interpreting or characterizing disease mechanisms, such as the Small Molecule Pathway Database (SMPDB). Using these and other well-known bioinformatic resources, clinicians are now able to make more precise dia作者: chastise 時間: 2025-3-26 09:10
Untargeted Metabolomics in Newborn Screening,patient outcomes. Breaking the diagnostic barrier can mean new research, new drugs, and ultimately increased survival. In this chapter, we overview the concept of untargeted metabolomics as applied to newborn screening, how it fares compared to the well-standardized tests of the targeted screening, 作者: miniature 時間: 2025-3-26 16:22 作者: 有毒 時間: 2025-3-26 17:30
Metabolomics of Rare Endocrine, Genetic Disease: A Focus on the Pituitary Gland,bolomic analysis techniques in pituitary disease will be a helpful clinical tool for significantly improving diagnosis and, potentially, the therapeutic approach by identifying highly specific disease biomarkers and novel molecular pathogenic mechanisms.作者: 狂怒 時間: 2025-3-27 00:24
Metabolomic Role in Personalized Medicine: An Update,ethod to provide the theoretical basis for individualized medical treatment. This chapter overviews clinical metabotyping, disease biomarker discovery, and pharmacometabolomics toward personalized medicine, improving drug efficacy. These three approaches enhance the understanding of the disease’s pa作者: tinnitus 時間: 2025-3-27 04:52 作者: 愛哭 時間: 2025-3-27 08:19 作者: 熱情的我 時間: 2025-3-27 11:38 作者: coltish 時間: 2025-3-27 14:40
https://doi.org/10.1007/978-3-658-11366-7cal system. Targeted and quantitative MS-based?assays?containing?relatively large panels of small molecules (metabolites) are routinely utilized for newborn screening (NBS), biochemical genetics testing, and toxicology. Broad nontargeted metabolomics investigations?have?found some utility in the afo作者: 沙漠 時間: 2025-3-27 20:37 作者: DAMP 時間: 2025-3-28 01:24 作者: 使更活躍 時間: 2025-3-28 02:48
Lothar Brock,Egbert Jahn,Reiner Steinwegpatient outcomes. Breaking the diagnostic barrier can mean new research, new drugs, and ultimately increased survival. In this chapter, we overview the concept of untargeted metabolomics as applied to newborn screening, how it fares compared to the well-standardized tests of the targeted screening, 作者: 容易懂得 時間: 2025-3-28 08:46
https://doi.org/10.1007/978-3-322-86202-0Ds can appear over the entire life span. Patients with particular MDs present a wide range of heterogeneous phenotypes with different levels of disease severity. The wide variety of leading causes and heterogenous phenotypes of MDs make diagnosing MDs notoriously challenging. Despite these challenge作者: 門閂 時間: 2025-3-28 11:55
https://doi.org/10.1007/978-3-322-86202-0bolomic analysis techniques in pituitary disease will be a helpful clinical tool for significantly improving diagnosis and, potentially, the therapeutic approach by identifying highly specific disease biomarkers and novel molecular pathogenic mechanisms.作者: 漂浮 時間: 2025-3-28 14:51
,Kernwaffen und regionale Stabilit?t,ethod to provide the theoretical basis for individualized medical treatment. This chapter overviews clinical metabotyping, disease biomarker discovery, and pharmacometabolomics toward personalized medicine, improving drug efficacy. These three approaches enhance the understanding of the disease’s pa作者: FLASK 時間: 2025-3-28 19:55 作者: BOLUS 時間: 2025-3-28 23:08
Stephanie L. Moon,Jeffrey Wiluszell as the utilization of nanomaterials as transducers are highlighted. The developments of multiplexed array biosensors for the simultaneous detection of multiple biomarkers and wearable biosensors are discussed as emerging diagnostic tools in metabolomics. The challenges and future perspectives in作者: 佛刊 時間: 2025-3-29 06:57 作者: arousal 時間: 2025-3-29 10:34
Mass Spectrometry-Based Metabolomics for the Clinical Laboratory, of known biomarkers for disease diagnosis and monitoring,?general health status evaluation, toxicology, and therapeutic drug monitoring. Although there are exceptions, MS-based assays in the clinical laboratory typically involve the utilization of analyte-specific calibration curves for quantitatio作者: ineluctable 時間: 2025-3-29 13:09
Metabolomics: A Pipeline for Biomarker Discovery in Genetic Diseases,ertain biological matrix. Metabolomic studies use advanced technologies (nuclear magnetic resonance (NMR) and mass spectrometry (MS)) with bioinformatics to identify and quantify a set of small molecules (such as carbohydrates, nucleic acids, amino acids, and lipids) present in a biological system. 作者: CANDY 時間: 2025-3-29 17:19 作者: FAR 時間: 2025-3-29 22:06
Untargeted Metabolomics in Newborn Screening,disorders at the presymptomatic stage, enabling early disease-modifying intervention that otherwise invariably leads to death or permanent damage if treated at the symptomatic stage. The advent of multiplex high-throughput assays involving chromatography coupled with mass spectroscopy enabled the an作者: genuine 時間: 2025-3-30 02:04
Untargeted Metabolomics, Targeted Care: The Clinical Utilities of Bedside Metabolomics,etabolic pathways of physiologically active cells and tissues, along with an improved resolution of high-throughput screening capabilities, brought forth the clinical metabolome. Clinicians can now take a metabolic snapshot while assessing their patients and receive invaluable information on patholo作者: 職業(yè) 時間: 2025-3-30 07:16 作者: 適宜 時間: 2025-3-30 12:04
Metabolomics of Rare Endocrine, Genetic Disease: A Focus on the Pituitary Gland,ique metabolomic disease profiles. In the last few years, metabolomic-derived biomarkers and quantitative traits have helped identify the underlying mechanisms for many rare endocrine diseases and demonstrated a high potential for use in precision medicine. Using the metabolomic platform has also pr作者: Fissure 時間: 2025-3-30 14:16
Metabolomics and Genetics of Rare Endocrine Disease: Adrenal, Parathyroid Glands, and Cystic Fibrosthe adrenal gland (hyperaldosteronism, primary adrenal insufficiency), parathyroid (hypoparathyroidism), and cystic fibrosis. Metabolomic profiling combined with genomics is increasingly being employed for improving understanding, clinical diagnosis, and management of these clinically challenging co作者: Irremediable 時間: 2025-3-30 19:47 作者: thrombus 時間: 2025-3-30 23:05
Lipidomic Profiling in Clinical Practice Using LC-MS,ved in health and disease. Currently, many lipidomic profiling applications are moving from research laboratories to clinical application, as lipidomics has the potential to be implemented into the clinical routine, complementing traditional clinical factors to improve the diagnosis, to stratify ris作者: Conclave 時間: 2025-3-31 03:46 作者: 玉米棒子 時間: 2025-3-31 05:30
